A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
No Thumbnail Available
Identifiers
Date
2020-11-01
Authors
Szabados, B. E.
Rodriguez-Vida, A.
Duran, I.
Crabb, S. J.
van-der-Heijden, M. S.
Pous, A. Font
Gravis, G.
Herranz, U. Anido
Protheroe, A.
Ravaud, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
Abstract
Background. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC).
Methods. This single arm, phase II study investigated two cycles of atezolizumab (1200mg given every 3 weeks) prior to RC in MIBC(T2-4aN0M0) (NCT02662309). The study included patients who were ineligible or refused neoadjuvant cisplatin-based chemotherapy and had transitional cell histology. Pathological complete response (pCR) was the primary endpoint. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification.
Description
MeSH Terms
Humans
Cystectomy
Neoadjuvant Therapy
Cystectomy
Neoadjuvant Therapy
DeCS Terms
Pacientes
Brazo
Cisplatino
Cistectomía
Histología
Neoplasias de la vejiga urinaria
Células
Quimioterapia
Reacción en cadena de la Polimerasa
Brazo
Cisplatino
Cistectomía
Histología
Neoplasias de la vejiga urinaria
Células
Quimioterapia
Reacción en cadena de la Polimerasa
CIE Terms
Keywords
Cisplatin, atezolizumab, Urinary Bladder Neoplasms, Muscles
Citation
Szabados, B. E. Rodriguez-Vida, A. Duran, I., Crabb, S. J., van-der-Heijden, M. S., Pous, A. Font et al. A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Ann. oncol.2020; (31);S1319